G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024

Stock Information for Black Diamond Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Black Diamond Therapeutics Inc.

G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
G1 Therapeutics to Participate in TD Cowen's 5th Annual Oncology Innovation Summit
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.